Trastuzumab Deruxtecan in Solid Tumours Harbouring HER2 Mutations
1. The objective response rate for trastuzumab deruxtecan was 29.4%. 2. Treatment-emergent adverse...
Read More
Oncology
Minimal Residual Disease negativity after Autologous Hematopoietic Cell Transplantation with lenalidomide maintenance predicts better long-term outcomes in myeloma
1. Achieving Minimal Residual Disease (MRD) negativity at baseline before lenalidomide...
Read More
Promising results with new oncolytic virus targeted at advanced solid tumors
1. The use of recombinant L-IFN adenovirus in patients with recurrent or refractory advanced solid...
Read More
Higher national health expenditure correlates with better lymphoid malignancy survival rates in European countries.
1. Lymphoid malignancy survival rates in European countries correlate with natation health...
Read More
#VisualAbstract: Overall Survival Improved with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo...
Read More
Afamitresgene autoleucel as an effective T-cell therapy for synovial sarcoma and liposarcoma
1. Overall response rate to afami-cel in both groups was 37%. 2. The majority of adverse-events...
Read More
Pembrolizumab enhances progression-free survival in patients with locally advanced cervical cancer
1. Progression-free survival at 24 months was higher in the pembrolizumab versus...
Read More
The addition of cisplatin to standard-of-care radiation therapy does not appear to improve progression-free survival for patients with localized recurrent endometrial cancer.
1. For patients with localized endometrial cancer recurrence, adding cisplatin to radiation...
Read More
Gefitinib with Chemotherapy in EGFR-Mutated Lung Cancer
1. The median overall survival was 17.6 months in the gefitinib group vs 27.5 months in the...
Read More
#VisualAbstract: Sentinel-node biopsy only is noninferior to completion of axillary lymph node dissection in breast cancer with sentinel-node metastases
1. The hazard ratio for recurrence or death comparing sentinel node biopsy only to completion...
Read More
Overall Survival Improved with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo...
Read More
Mitoxantrone is superior to liposomal daunorubicin in MRD (measurable residual disease)-guided treatment of AML in pediatric cases
1. Mitoxantrone enhances five-year event-free survival over liposomal daunorubicin in MRD-guided...
Read More
Novel Oral Synthetic Genistein Nanosuspension May Protect Against Negative Effects Of Radiation Therapy In Lung Cancer
BIO 300 use led to reduced levels of a proinflammatory/profibrotic cytokine associated with lung...
Read More
Neoadjuvant chemotherapy does not appear to significantly improve disease-free survival in patients with locally advanced colon cancer
1. When compared to upfront surgery, neoadjuvant chemotherapy using mFOLFOX or CAPOX did not...
Read More
Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases
1. The hazard ratio for recurrence or death comparing sentinel node biopsy only to completion...
Read More
#VisualAbstract: Imetelstat improves blood transfusion independence in lower-risk myelodysplastic syndromes
1. Significantly more patients in the imetelstat group achieved RBC transfusion independence at 8...
Read More
#VisualAbstract: Pazopanib does not improve disease-free survival post-metastasectomy for renal cell carcinoma patients
1. Pazopanib did not improve disease-free survival in post-metastasectomy renal cell carcinoma...
Read More
#VisualAbstract: Iptacopan improves hematologic and clinical outcomes in paroxysmal nocturnal hemoglobinuria
1. In two clinical trials, iptacopan in patients with paroxysmal nocturnal hemoglobinuria (PNH)...
Read More
Though associated with rising costs, the majority of publicly-funded cancer medications included in Ontario, Canada are those with substantial survival benefit
1. Roughly 65% of the cancer medication budget is allocated to treatments that provide improvement...
Read More
Neoadjuvant Dual vs Single Checkpoint Inhibitors in High-Risk Melanoma
1. The pathological response rate had an OR of 3.16 when comparing neoadjuvant dual vs single...
Read More